Saluda Medical, (ASX:SLD)
ASX announcement history & article coverage
Transparent by design.
Announcments by Saluda Medical, (ASX:SLD) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
FY26 Consolidated Financial Statements
CEO Transition
Change in substantial holding
FY26 Results Presentation
Saluda Medical delivers 28% FY26 revenue growth, expands US market penetration, and guides for continued strong FY27 growth
FY26 Full Year Results
Saluda Medical FY26 revenue beats guidance with strong US and international growth; FDA approves CAP24 paddle lead; FY27 guidance signals improved operating leverage
Preliminary Final Report
Saluda Medical reports 28% revenue growth to $90.2M, flat $149.6M net loss, completed IPO and common stock financing, but faces going concern risks
FY26 Results & Webinar, 2026 AGM Notification
Quarterly Investor Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
Saluda Medical beats FY26 revenue guidance with 28% growth, FDA approves CAP24 paddle lead expanding US market opportunity
First U.S. Surgical Cases Using CAP24 Paddle Leads
Change in substantial holding
Notification of cessation of securities - SLD
Notification regarding unquoted securities - SLD
Notification regarding unquoted securities - SLD
SLD Draws US$25m Second Tranche of Credit Facility
SLD Receives FDA Approval for CAP24 Surgical Paddle Lead
Saluda Medical gains FDA approval for CAP24 surgical paddle lead, expanding U.S. market reach
